Is Panax ginseng the same as Siberian ginseng or American ginseng?

No. Panax ginseng (also called Korean or Asian ginseng) is a distinct species from Eleutherococcus senticosus (Siberian ginseng, which isn't a true Panax) and Panax quinquefolius (American ginseng). They share some broadly similar traditional uses and contain related compounds, but their ginsenoside profiles differ meaningfully, and they shouldn't be treated as interchangeable in research or in practice.

What are ginsenosides and why do they matter?

Ginsenosides are triterpenoid saponins considered the primary bioactive constituents of Panax ginseng. Over 150 have been identified. They are the compounds most studied in preclinical and clinical research on ginseng, and standardised ginseng extracts typically specify their guaranteed ginsenoside content. Their bioavailability from oral intake depends partly on gut bacterial conversion to active metabolites, which varies between individuals.

Can I buy Panax ginseng products legally in Australia?

Yes. Panax ginseng is not scheduled under Australia's Poisons Standard and is available as a complementary medicine. Products sold in Australia should carry an AUST L (listed) or AUST R (registered) number on their label, indicating they are entered on the Australian Register of Therapeutic Goods (ARTG). Listed products have been assessed for safety and quality by the TGA, but not for efficacy.

Does red ginseng differ from white ginseng?

Yes, chemically. White ginseng is simply dried raw root; red ginseng is steamed before drying. The heat of steaming drives chemical transformations that produce 'rare' ginsenosides — including Rg3, Rk1 and Rg5 — not found in significant quantities in white ginseng. This means their constituent profiles are distinct, and studies conducted on one form don't automatically apply to the other.

Are there any drug interactions I should know about with Panax ginseng?

Preclinical research has identified potential effects of ginsenosides on cytochrome P450 enzymes involved in drug metabolism, raising theoretical interaction concerns with anticoagulants and some cardiovascular medicines. The clinical significance at typical doses is not firmly established. Anyone taking prescription medications should speak with their pharmacist or prescribing doctor before adding ginseng products to their routine.

Panax Ginseng: Traditional Use, Constituents and Evidence

By Naomi Ellison · 4 May 2026 · 9 min read

A microscope being used to examine a substance

Panax ginseng is one of the most historically documented botanical substances on the planet, and it still turns up on pharmacy shelves, in tea bags and in energy-drink ingredient lists. It is simultaneously ancient and stubbornly current. Anyone who reads seriously about phytomedicine ends up running into it sooner or later.

The name itself is a clue. Panax comes from the Greek for "all-healing," which tells you something about the ambition of those who named it. Whether that ambition is justified by the science is a more complicated question, and it is the one this article tries to answer carefully, without overselling.

A brief history of traditional use

Panax ginseng is native to the mountain forests of northeast China, Korea and the Russian Far East. Written records of its use in Chinese medicine date back at least two thousand years. The Shennong Bencao Jing, one of the foundational texts of traditional Chinese medicine, compiled sometime around the first to second century CE, classifies it as a superior-grade tonic. The term adaptogen came much later, coined in the 1940s by Soviet pharmacologist Nikolai Lazarev. The conceptual category it describes, a substance believed to help an organism resist nonspecific stressors, maps fairly closely to how practitioners of traditional Chinese medicine described ginseng's function for centuries.

Worth stressing: "adaptogen" is a descriptive concept, not a regulated or formally validated pharmacological class. It tells you how a tradition framed a plant, and says little about what a modern trial has demonstrated. Other herbs get grouped under the same label, including ashwagandha and Rhodiola rosea, and the same caution applies to each.

In Korean medicine (where the cultivated variety Panax ginseng C.A.Mey. is often called insam), ginseng roots have historically been categorised by age and processing method. Fresh root, white ginseng (dried), and red ginseng (steam-processed before drying) are each considered distinct preparations with different properties. The steaming step in red ginseng production creates particular chemical changes in the root, a point that becomes relevant when we look at what's actually in it. For a general reference on the species, its botany and its naming, the Wikipedia entry on Panax ginseng is a reasonable starting point.

Key constituents: ginsenosides and beyond

The primary bioactive constituents of Panax ginseng are a group of triterpenoid saponins collectively known as ginsenosides (also written ginsenosides or, in older Korean literature, panaxosides). More than 150 individual ginsenosides have been identified, grouped broadly into protopanaxadiol (PPD) types and protopanaxatriol (PPT) types, plus an oleanane-type called Ro. The grouping reflects the underlying chemical skeleton, and it matters because small structural differences, such as which sugar groups are attached, change how a molecule behaves in the body.

The most studied ginsenosides include Rb1, Rb2, Rc, Rd (all PPD-type) and Rg1, Re, Rf (PPT-type). Red ginseng processing generates additional "rare" ginsenosides, Rg3, Rg5, Rk1 and others, through heat-driven transformation of the more abundant parent compounds. This is why the chemical profile of red and white ginseng preparations differs substantially, and why comparing studies across processing methods is tricky.

Beyond ginsenosides, the root contains polysaccharides (notably ginsan), polyacetylenes, peptides, and several volatile compounds. Some researchers have noted possible interactions between ginsenosides and receptor pathways more commonly associated with other botanical systems, though the picture remains genuinely unsettled. For context on how plant-derived compounds can engage receptor signalling in complex ways, our glossary entry on the endocannabinoid system gives a useful frame for thinking about ligand–receptor pharmacology more broadly, even if ginseng's primary pharmacology runs through different pathways entirely.

Why bioavailability complicates the picture

Bioavailability is a real complication with ginsenosides. Most are poorly absorbed in their original form from the gut; colonic bacteria transform them into more readily absorbed metabolites (compound K being the most studied). This means the same oral dose can produce quite different systemic exposure depending on a person's gut microbiome composition, a nuance that many older trials simply didn't account for.

Think about what that does to a study. Two participants can swallow an identical preparation and end up with different circulating metabolites. If a trial doesn't measure or control for that, the average result can blur together people who responded very differently at the biochemical level. It is one reason a single positive or negative trial should be read cautiously.

What the research on Panax ginseng actually shows

I'll be honest: the published literature on Panax ginseng is both large and frustrating. There are hundreds of in vitro and animal studies, a reasonable number of small human trials, and a much smaller pool of well-designed, adequately powered randomised controlled trials. Systematic reviews regularly flag concerns about trial heterogeneity (different preparations, different ginsenoside profiles, wildly varying dose ranges, inconsistent outcome measures), high risk of bias in earlier studies, and publication bias toward positive results.

Research has examined ginsenosides across a range of areas including cognitive function, fatigue, immune parameters, glycaemic markers, and physical performance. Some trials report statistically significant findings; others don't replicate them. The Cochrane-style systematic reviews that have examined specific applications tend to land on "promising but insufficient evidence to draw firm conclusions." That is not a dismissal, it's an accurate statement of where the science sits right now.

A useful habit when reading any of this: separate laboratory and animal findings from human outcomes. A compound that changes a marker in a cell culture has not thereby shown a benefit in a person. Likewise, a small trial with a short follow-up can look striking and then fade when larger, better-controlled work is done. Statistical significance and clinical meaningfulness are also different things.

One area where the pharmacology is reasonably well characterised mechanistically is pharmacokinetics: we know quite a lot about how ginsenosides are metabolised, the role of gut flora in producing active metabolites, and how processing method affects constituent profile. That foundational chemistry work is solid. The clinical translation is what lags behind.

In my view, some of the enthusiasm around ginseng in the wellness market has run well ahead of what the clinical evidence can actually support. That's not unusual in phytomedicine; it's arguably the norm, but it's worth naming plainly. The same pattern shows up with other long-traditional herbs such as ginkgo biloba, where a long history of use is sometimes quietly treated as if it were trial evidence.

Standardisation and quality: not a minor detail

One of the persistent problems in ginseng research is that "ginseng" is not a single, consistent thing. Ginsenoside content varies by plant age (roots are typically harvested at four to six years), growing conditions, geographic origin, post-harvest processing, and extraction method. A product labelled "ginseng extract" without further specification could contain anywhere from trivial to significant concentrations of the target compounds.

This is where standardised extracts matter. A standardised extract specifies a guaranteed minimum content of a named marker compound (commonly total ginsenosides, expressed as a percentage). It doesn't solve all problems, since marker compounds may not be the most pharmacologically active ones, but it at least makes trial replication and inter-study comparison more meaningful.

When reading a label or a study, a few questions are worth asking. Which part of the plant was used, and at what age? Was it white or red ginseng? Is the marker compound named, and is the amount stated per serve rather than just per capsule of raw material? A common mistake is to treat "Panax ginseng" on the front of a pack as equivalent to the material used in a published trial. Related species such as American ginseng and Siberian ginseng are different plants, and results do not transfer neatly between them.

Regulation in Australia: the TGA and complementary medicines

In Australia, Panax ginseng products are generally regulated as complementary medicines under the Therapeutic Goods Administration (TGA) framework. Most are listed medicines, they appear on the Australian Register of Therapeutic Goods (ARTG) as "listed" rather than "registered" products. Listed complementary medicines are assessed for safety and quality by the TGA, but not for efficacy; the sponsor self-assesses evidence and must hold it on file, but it is not reviewed at the time of listing.

This is a meaningful distinction for consumers. A listed product with an AUST L number is not the same as a registered medicine with an AUST R number that has undergone full TGA efficacy evaluation. Ginseng products also cannot carry indications that make therapeutic claims beyond those permitted for listed medicines under the TGA's evidence guidelines. Claims must be supported by evidence of the level the TGA specifies for complementary medicines, and serious-disease representations are prohibited entirely.

Products must also comply with Good Manufacturing Practice (GMP) requirements. In principle, this should mean consistent product quality; in practice, auditing and enforcement has historically been variable across the industry, though the TGA has strengthened its approach in recent years.

Unlike some botanical substances (kava import controls under Australian Border Force and the TGA's scheduling of kava is a useful comparison case for how differently various botanicals can be treated; see our kava article), ginseng has no specific scheduling under the current Poisons Standard. It sits comfortably in the complementary medicines space without the access restrictions that apply to, say, Schedule 4 or Schedule 8 substances. For context on those frameworks, see our pages on Schedule 4 (Prescription Only) and Schedule 8 (Controlled Drug) medicines.

Interactions and safety signals

Ginseng is widely regarded as well-tolerated at commonly used doses in healthy adults. That said, the pharmacology is not inert. Ginsenosides have demonstrated effects on cytochrome P450 enzymes in preclinical settings, which raises the theoretical possibility of herb-drug interactions, particularly with anticoagulants and certain cardiovascular medicines. The clinical significance of these interactions in real-world doses remains an open question, but it's the kind of thing that warrants a conversation with a pharmacist or prescriber if someone is taking relevant medications.

Cytochrome P450 enzymes are the liver's main machinery for processing many medicines, so anything that nudges their activity can, in theory, change how much of a drug stays in circulation. "In theory" is the operative phrase here. Preclinical findings flag a question; they do not answer it.

Insomnia and mild gastrointestinal symptoms are the most commonly reported adverse effects in trials. There's also a reasonable body of literature cautioning against combining high-dose ginseng with stimulants, though again the clinical data are thin.

None of this makes ginseng dangerous in any absolute sense. But "natural" and "safe in any context" are not synonyms, a principle worth holding firmly whenever plant medicine enters the conversation.

Sources

Naomi Ellison, Botanical & phytomedicine writer

Common questions

Is Panax ginseng the same as Siberian ginseng or American ginseng?: No. Panax ginseng (also called Korean or Asian ginseng) is a distinct species from Eleutherococcus senticosus (Siberian ginseng, which isn't a true Panax) and Panax quinquefolius (American ginseng). They share some broadly similar traditional uses and contain related compounds, but their ginsenoside profiles differ meaningfully, and they shouldn't be treated as interchangeable in research or in practice.
What are ginsenosides and why do they matter?: Ginsenosides are triterpenoid saponins considered the primary bioactive constituents of Panax ginseng. Over 150 have been identified. They are the compounds most studied in preclinical and clinical research on ginseng, and standardised ginseng extracts typically specify their guaranteed ginsenoside content. Their bioavailability from oral intake depends partly on gut bacterial conversion to active metabolites, which varies between individuals.
Can I buy Panax ginseng products legally in Australia?: Yes. Panax ginseng is not scheduled under Australia's Poisons Standard and is available as a complementary medicine. Products sold in Australia should carry an AUST L (listed) or AUST R (registered) number on their label, indicating they are entered on the Australian Register of Therapeutic Goods (ARTG). Listed products have been assessed for safety and quality by the TGA, but not for efficacy.
Does red ginseng differ from white ginseng?: Yes, chemically. White ginseng is simply dried raw root; red ginseng is steamed before drying. The heat of steaming drives chemical transformations that produce 'rare' ginsenosides — including Rg3, Rk1 and Rg5 — not found in significant quantities in white ginseng. This means their constituent profiles are distinct, and studies conducted on one form don't automatically apply to the other.
Are there any drug interactions I should know about with Panax ginseng?: Preclinical research has identified potential effects of ginsenosides on cytochrome P450 enzymes involved in drug metabolism, raising theoretical interaction concerns with anticoagulants and some cardiovascular medicines. The clinical significance at typical doses is not firmly established. Anyone taking prescription medications should speak with their pharmacist or prescribing doctor before adding ginseng products to their routine.